Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy

US11014989B2 · kind B2 · utility

Assignee

• CELLECTIS · FR

Inventors

• Julianne Smith · New York, US
• Julien Valton · New York, US
• Alexandre Juillerat · New York, US
• Philippe Duchateau · Étampes, FR
• Barbra Johnson SASU · San Francisco, US
• Arvind Rajpal · San Francisco, US

Key dates

• Filing date: Jan 25, 2016
• Grant date: May 25, 2021
• Expiry date: Jul 4, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2015/1028
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.